Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers

Can Respir J. 2000 Jul-Aug;7(4):313-9. doi: 10.1155/2000/254213.

Abstract

Background: A direct comparison of the protective effects of single and regular doses of inhaled glucocorticoid on allergen-induced asthmatic responses and inflammation has not been made.

Objective: To compare the effects of pretreatment with fluticasone 250 microg 30 min before allergen inhalation and two weeks of 250 microg twice daily (last dose 24 h before challenge) with single and regular (twice daily) placebo doses on early and late asthmatic responses, induced sputum cell counts and measures of eosinophil activation at 7 h and 24 h, and methacholine airway responsiveness at 24 h.

Patients and methods: Ten mild asthmatic patients were studied in a randomized, double-blind, placebo controlled crossover study.

Results: Regular fluticasone increased the baseline mean provocative concentration of methacholine to cause a 20% fall (PC20) in forced expiratory volume in 1 s (FEV1) from 2.6 to 6.4 mg/mL (P<0.05) and lowered the eosinophil count from 3.1% to 0.4% (P<0.05) compared with regular placebo. Neither single nor regular fluticasone had any effect on the early asthmatic response. Single fluticasone attenuated the late asthmatic response, the mean +/- SEM maximum percentage fall in FEV1 (10.8+/-3.6 compared with single placebo 18. 8+/-3.5, P=0.03), the allergen-induced increase of airway responsiveness (P<0.05), and the eosinophilia (P<0.005) and activated eosinophils at 7 h (P<0.01) but not at 24 h. Regular fluticasone also attenuated the late asthmatic response (11.1+/-2.5) compared with regular placebo (19.6+/-4.5), but this was not statistically significant and did not protect against the induced increase in airway responsiveness or the sputum eosinophilia.

Conclusion: Two weeks of regular inhaled fluticasone discontinued 24 h before allergen challenge does not offer any additional protection against the early or late asthmatic responses, increased airway responsiveness or sputum eosinophilia compared with a single dose of 250 microg immediately before allergen challenge, despite increasing baseline PC20 and decreasing sputum eosinophilia prechallenge. The significance of the protective effect of a single dose of inhaled steroid before an allergen inhalation and the duration of the protective effect need further investigation.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Allergens
  • Androstadienes / administration & dosage
  • Androstadienes / therapeutic use*
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / immunology
  • Bronchial Provocation Tests
  • Bronchoconstrictor Agents
  • Cross-Over Studies
  • Double-Blind Method
  • Eosinophils / immunology
  • Female
  • Fluticasone
  • Glucocorticoids
  • Humans
  • Male
  • Methacholine Chloride
  • Sputum / cytology
  • Sputum / immunology

Substances

  • Allergens
  • Androstadienes
  • Anti-Inflammatory Agents
  • Bronchoconstrictor Agents
  • Glucocorticoids
  • Methacholine Chloride
  • Fluticasone